Oropharyngeal Dysphagia
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Cook MyoSitePA - Pittsburgh
2 programs1
1
Autologous Muscle Derived Cells for Gastro-Intestinal RepairPhase 1/21 trial
Autologous Muscle Derived Cells for Gastro-Intestinal RepairPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Cook MyoSiteAutologous Muscle Derived Cells for Gastro-Intestinal Repair
Cook MyoSiteAutologous Muscle Derived Cells for Gastro-Intestinal Repair
Clinical Trials (2)
Total enrollment: 84 patients across 2 trials
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
Start: May 2022Est. completion: Dec 202666 patients
Phase 1/2Active Not Recruiting
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Start: May 2017Est. completion: Dec 202618 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.